Literature DB >> 26819051

Structural modeling of JAK1 mutations in T-cell acute lymphoblastic leukemia reveals a second contact site between pseudokinase and kinase domains.

Kirsten Canté-Barrett1, Joost C M Uitdehaag2, Jules P P Meijerink3.   

Abstract

Entities:  

Keywords:  JAK1; T-cell acute lymphoblastic leukemia; TYK2; activating mutation; structure

Mesh：

Substances：

Year:  2016        PMID： 26819051      PMCID： PMC5004377          DOI： 10.3324/haematol.2015.138248

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  19 in total

1.  Identification of imidazo-pyrrolopyridines as novel and potent JAK1 inhibitors.

Authors:  Janusz J Kulagowski; Wade Blair; Richard J Bull; Christine Chang; Gauri Deshmukh; Hazel J Dyke; Charles Eigenbrot; Nico Ghilardi; Paul Gibbons; Trevor K Harrison; Peter R Hewitt; Marya Liimatta; Christopher A Hurley; Adam Johnson; Tony Johnson; Jane R Kenny; Pawan Bir Kohli; Robert J Maxey; Rohan Mendonca; Kyle Mortara; Jeremy Murray; Raman Narukulla; Steven Shia; Micah Steffek; Savita Ubhayakar; Mark Ultsch; Anne van Abbema; Stuart I Ward; Bohdan Waszkowycz; Mark Zak
Journal:  J Med Chem       Date:  2012-06-11       Impact factor: 7.446

2.  JAK1 mutations are not frequent events in adult T-ALL: a GRAALL study.

Authors:  Vahid Asnafi; Sandrine Le Noir; Ludovic Lhermitte; Claude Gardin; Faézeh Legrand; Xavier Vallantin; Jean-Valère Malfuson; Norbert Ifrah; Hervé Dombret; Elizabeth Macintyre
Journal:  Br J Haematol       Date:  2009-09-18       Impact factor: 6.998

3.  Discovering what makes STAT signaling TYK in T-ALL.

Authors:  Lorena Fontan; Ari Melnick
Journal:  Cancer Discov       Date:  2013-05       Impact factor: 39.397

4.  Structure of the pseudokinase-kinase domains from protein kinase TYK2 reveals a mechanism for Janus kinase (JAK) autoinhibition.

Authors:  Patrick J Lupardus; Mark Ultsch; Heidi Wallweber; Pawan Bir Kohli; Adam R Johnson; Charles Eigenbrot
Journal:  Proc Natl Acad Sci U S A       Date:  2014-05-19       Impact factor: 11.205

5.  A novel recurrent NPM1-TYK2 gene fusion in cutaneous CD30-positive lymphoproliferative disorders.

Authors:  Thirunavukkarasu Velusamy; Mark J Kiel; Anagh A Sahasrabuddhe; Delphine Rolland; Catherine A Dixon; Nathanael G Bailey; Bryan L Betz; Noah A Brown; Alexandra C Hristov; Ryan A Wilcox; Roberto N Miranda; L Jeffrey Medeiros; Yoon K Jeon; Kedar V Inamdar; Megan S Lim; Kojo S J Elenitoba-Johnson
Journal:  Blood       Date:  2014-10-27       Impact factor: 22.113

Review 6.  JAK kinase targeting in hematologic malignancies: a sinuous pathway from identification of genetic alterations towards clinical indications.

Authors:  Lorraine Springuel; Jean-Christophe Renauld; Laurent Knoops
Journal:  Haematologica       Date:  2015-10       Impact factor: 9.941

7.  Oncogenic IL7R gain-of-function mutations in childhood T-cell acute lymphoblastic leukemia.

Authors:  Priscila P Zenatti; Daniel Ribeiro; Wenqing Li; Linda Zuurbier; Milene C Silva; Maddalena Paganin; Julia Tritapoe; Julie A Hixon; André B Silveira; Bruno A Cardoso; Leonor M Sarmento; Nádia Correia; Maria L Toribio; Jörg Kobarg; Martin Horstmann; Rob Pieters; Silvia R Brandalise; Adolfo A Ferrando; Jules P Meijerink; Scott K Durum; J Andrés Yunes; João T Barata
Journal:  Nat Genet       Date:  2011-09-04       Impact factor: 38.330

8.  TYK2-STAT1-BCL2 pathway dependence in T-cell acute lymphoblastic leukemia.

Authors:  Takaomi Sanda; Jeffrey W Tyner; Alejandro Gutierrez; Vu N Ngo; Jason Glover; Bill H Chang; Arla Yost; Wenxue Ma; Angela G Fleischman; Wenjun Zhou; Yandan Yang; Maria Kleppe; Yebin Ahn; Jessica Tatarek; Michelle A Kelliher; Donna S Neuberg; Ross L Levine; Richard Moriggl; Mathias Müller; Nathanael S Gray; Catriona H M Jamieson; Andrew P Weng; Louis M Staudt; Brian J Druker; A Thomas Look
Journal:  Cancer Discov       Date:  2013-03-07       Impact factor: 39.397

9.  Somatic mutations of JAK1 and JAK3 in acute leukemias and solid cancers.

Authors:  Eun Goo Jeong; Min Sung Kim; Hyo Kyung Nam; Chang Ki Min; Seok Lee; Yeun Jun Chung; Nam Jin Yoo; Sug Hyung Lee
Journal:  Clin Cancer Res       Date:  2008-06-15       Impact factor: 12.531

10.  Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia.

Authors:  Elisabetta Flex; Valentina Petrangeli; Lorenzo Stella; Sabina Chiaretti; Tekla Hornakova; Laurent Knoops; Cristina Ariola; Valentina Fodale; Emmanuelle Clappier; Francesca Paoloni; Simone Martinelli; Alessandra Fragale; Massimo Sanchez; Simona Tavolaro; Monica Messina; Giovanni Cazzaniga; Andrea Camera; Giovanni Pizzolo; Assunta Tornesello; Marco Vignetti; Angela Battistini; Hélène Cavé; Bruce D Gelb; Jean-Christophe Renauld; Andrea Biondi; Stefan N Constantinescu; Robin Foà; Marco Tartaglia
Journal:  J Exp Med       Date:  2008-03-24       Impact factor: 14.307
View more
  4 in total

1.  JAK Pseudokinase Domain Variants Highlight nRTK VUSs Identified with Next-Generation Sequencing in Solid Tumor Patients.

Authors:  Matthew K Stein; Lindsay K Morris; Mike G Martin
Journal:  Pathol Oncol Res       Date:  2018-06-03       Impact factor: 3.201

Review 2.  Therapeutic targeting of IL-7Rα signaling pathways in ALL treatment.

Authors:  Sarah D Cramer; Peter D Aplan; Scott K Durum
Journal:  Blood       Date:  2016-06-06       Impact factor: 22.113

3.  MEK and PI3K-AKT inhibitors synergistically block activated IL7 receptor signaling in T-cell acute lymphoblastic leukemia.

Authors:  K Canté-Barrett; J A P Spijkers-Hagelstein; J G C A M Buijs-Gladdines; J C M Uitdehaag; W K Smits; J van der Zwet; R C Buijsman; G J R Zaman; R Pieters; J P P Meijerink
Journal:  Leukemia       Date:  2016-04-22       Impact factor: 11.528

4.  Characterization of JAK1 Pseudokinase Domain in Cytokine Signaling.

Authors:  Juuli Raivola; Teemu Haikarainen; Olli Silvennoinen
Journal:  Cancers (Basel)       Date:  2019-12-27       Impact factor: 6.639
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.